220 related articles for article (PubMed ID: 29084207)
1. Upregulation of the ALDOA/DNA-PK/p53 pathway by dietary restriction suppresses tumor growth.
Ma D; Chen X; Zhang PY; Zhang H; Wei LJ; Hu S; Tang JZ; Zhou MT; Xie C; Ou R; Xu Y; Tang KF
Oncogene; 2018 Feb; 37(8):1041-1048. PubMed ID: 29084207
[TBL] [Abstract][Full Text] [Related]
2. Loss-of-Function Genetic Screening Identifies Aldolase A as an Essential Driver for Liver Cancer Cell Growth Under Hypoxia.
Niu Y; Lin Z; Wan A; Sun L; Yan S; Liang H; Zhan S; Chen D; Bu X; Liu P; Chen C; He W; Lu X; Wan G
Hepatology; 2021 Sep; 74(3):1461-1479. PubMed ID: 33813748
[TBL] [Abstract][Full Text] [Related]
3. Fructose-Bisphosphate Aldolase A Regulates Hypoxic Adaptation in Hepatocellular Carcinoma and Involved with Tumor Malignancy.
Li X; Jiang F; Ge Z; Chen B; Yu J; Xin M; Wang J; An L; Wei J; Wu L
Dig Dis Sci; 2019 Nov; 64(11):3215-3227. PubMed ID: 31041640
[TBL] [Abstract][Full Text] [Related]
4. Aldolase A promotes proliferation and G
Fu H; Gao H; Qi X; Zhao L; Wu D; Bai Y; Li H; Liu X; Hu J; Shao S
Cancer Commun (Lond); 2018 May; 38(1):18. PubMed ID: 29764507
[TBL] [Abstract][Full Text] [Related]
5. High expression of fructose-bisphosphate aldolase A induces progression of renal cell carcinoma.
Huang Z; Hua Y; Tian Y; Qin C; Qian J; Bao M; Liu Y; Wang S; Cao Q; Ju X; Wang Z; Gu M
Oncol Rep; 2018 Jun; 39(6):2996-3006. PubMed ID: 29693182
[TBL] [Abstract][Full Text] [Related]
6. Ku80 functions as a tumor suppressor in hepatocellular carcinoma by inducing S-phase arrest through a p53-dependent pathway.
Wei S; Xiong M; Zhan DQ; Liang BY; Wang YY; Gutmann DH; Huang ZY; Chen XP
Carcinogenesis; 2012 Mar; 33(3):538-47. PubMed ID: 22226916
[TBL] [Abstract][Full Text] [Related]
7. miR-122-5p Inhibits the Proliferation, Invasion and Growth of Bile Duct Carcinoma Cells by Targeting ALDOA.
Xu Z; Liu G; Zhang M; Zhang Z; Jia Y; Peng L; Zhu Y; Hu J; Huang R; Sun X
Cell Physiol Biochem; 2018; 48(6):2596-2606. PubMed ID: 30121648
[TBL] [Abstract][Full Text] [Related]
8. The signaling pathways that mediate the anti-cancer effects of caloric restriction.
Lu Y; Tao F; Zhou MT; Tang KF
Pharmacol Res; 2019 Mar; 141():512-520. PubMed ID: 30641278
[TBL] [Abstract][Full Text] [Related]
9. 1,25(OH)
Huang J; Yang G; Huang Y; Zhang S
Biochimie; 2018 Mar; 146():28-34. PubMed ID: 29158005
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of PRAME Suppresses Proliferation and Promotes Apoptosis in Hepatocellular Carcinoma Through the Activation of P53 Mediated Pathway.
Zhu H; Wang J; Yin J; Lu B; Yang Q; Wan Y; Jia C
Cell Physiol Biochem; 2018; 45(3):1121-1135. PubMed ID: 29439259
[TBL] [Abstract][Full Text] [Related]
11. Pseudogene PDIA3P1 promotes cell proliferation, migration and invasion, and suppresses apoptosis in hepatocellular carcinoma by regulating the p53 pathway.
Kong Y; Zhang L; Huang Y; He T; Zhang L; Zhao X; Zhou X; Zhou D; Yan Y; Zhou J; Xie H; Zhou L; Zheng S; Wang W
Cancer Lett; 2017 Oct; 407():76-83. PubMed ID: 28823960
[TBL] [Abstract][Full Text] [Related]
12. The E3 Ligase RING1 Targets p53 for Degradation and Promotes Cancer Cell Proliferation and Survival.
Shen J; Li P; Shao X; Yang Y; Liu X; Feng M; Yu Q; Hu R; Wang Z
Cancer Res; 2018 Jan; 78(2):359-371. PubMed ID: 29187402
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of PRRX1 via the p53-dependent signaling pathway predicts poor prognosis in hepatocellular carcinoma.
Fan M; Shen J; Liu H; Wen Z; Yang J; Yang P; Liu K; Chang Y; Duan J; Lu K
Oncol Rep; 2017 Aug; 38(2):1083-1090. PubMed ID: 28677793
[TBL] [Abstract][Full Text] [Related]
14. Disruption of a regulatory loop between DUSP1 and p53 contributes to hepatocellular carcinoma development and progression.
Hao PP; Li H; Lee MJ; Wang YP; Kim JH; Yu GR; Lee SY; Leem SH; Jang KY; Kim DG
J Hepatol; 2015 Jun; 62(6):1278-86. PubMed ID: 25617504
[TBL] [Abstract][Full Text] [Related]
15. The antitumor role of a newly discovered α-d-glucan from Holotrichia diomphalia Bates as a selective blocker of aldolase A.
Wang J; Li Z; Yang X; Qiao Y; Feng C; Yu S; Jing H; Liu W; Ren L; Duan Q; Li XQ; Cao W
Carbohydr Polym; 2021 Mar; 255():117532. PubMed ID: 33436261
[TBL] [Abstract][Full Text] [Related]
16. NKD1 correlates with a poor prognosis and inhibits cell proliferation by inducing p53 expression in hepatocellular carcinoma.
Zhang S; Li J; Wang X
Tumour Biol; 2016 Oct; 37(10):14059-14067. PubMed ID: 27507614
[TBL] [Abstract][Full Text] [Related]
17. ZNF692 drives malignant development of hepatocellular carcinoma cells by promoting ALDOA-dependent glycolysis.
Meng W; Lu X; Wang G; Xiao Q; Gao J
Funct Integr Genomics; 2024 Mar; 24(2):53. PubMed ID: 38453820
[TBL] [Abstract][Full Text] [Related]
18. MKL-1-induced PINK1-AS overexpression contributes to the malignant progression of hepatocellular carcinoma via ALDOA-mediated glycolysis.
Wang J; Zhang HM; Dai ZT; Huang Y; Liu H; Chen Z; Wu Y; Liao XH
Sci Rep; 2022 Dec; 12(1):21283. PubMed ID: 36494481
[TBL] [Abstract][Full Text] [Related]
19. EBF1-Mediated Upregulation of Ribosome Assembly Factor PNO1 Contributes to Cancer Progression by Negatively Regulating the p53 Signaling Pathway.
Shen A; Chen Y; Liu L; Huang Y; Chen H; Qi F; Lin J; Shen Z; Wu X; Wu M; Li Q; Qiu L; Yu N; Sferra TJ; Peng J
Cancer Res; 2019 May; 79(9):2257-2270. PubMed ID: 30862720
[TBL] [Abstract][Full Text] [Related]
20. KU-0060648 inhibits hepatocellular carcinoma cells through DNA-PKcs-dependent and DNA-PKcs-independent mechanisms.
Chen MB; Zhou ZT; Yang L; Wei MX; Tang M; Ruan TY; Xu JY; Zhou XZ; Chen G; Lu PH
Oncotarget; 2016 Mar; 7(13):17047-59. PubMed ID: 26933997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
